GlassScriptPhysician profile
Steven J Maestrello
NPI 1154328938
$8,548.18
in general payments reported to CMS, 2019-2025
37 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $860 · 2021: $592 · 2022: $1,288 · 2023: $1,391 · 2024: $1,605 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,857 · Education: $96.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,857.27 |
| Education | $96.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,296.89 | 2019-2025 | Tavneos, Evenity, Krystexxa |
| Abbvie INC. | $1,079.20 | 2019-2025 | |
| Pfizer INC. | $733.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $609.04 | 2019-2025 | |
| Janssen Biotech, INC. | $607.15 | 2019-2024 | Tremfya, Remicade, Simponi Aria |
| Lilly USA, LLC | $594.55 | 2019-2024 | Taltz, Zepbound |
| Ucb, INC. | $382.49 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $298.89 | 2019-2025 | Orencia |
| Genentech USA, INC. | $296.37 | 2019-2025 | Actemra, Gazyva |
| Mallinckrodt Hospital Products INC. | $295.76 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $292.14 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $249.90 | 2019-2025 | Benlysta |
| Radius Health, INC. | $230.26 | 2022-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $171.30 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $163.06 | 2021-2023 | Krystexxa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.87 | 2019-2025 | Spevigo, Cyltezo |
| Aurinia Pharma U.S., INC. | $136.15 | 2021-2025 | Lupkynis |
| Sandoz INC. | $135.13 | 2023-2025 | Hyrimoz |
| Fresenius Kabi USA, LLC | $108.33 | 2023-2025 | Idacio |
| Genzyme Corporation | $99.55 | 2023-2025 | |
| Organon LLC | $95.33 | 2023-2025 | Renflexis, Hadlima, Nexplanon |
| Fidia Pharma USA INC. | $65.84 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $64.78 | 2021-2023 | Arcalyst |
| Tersera Therapeutics LLC | $54.33 | 2022-2024 | Quzyttir |
| Regeneron Healthcare Solutions, INC. | $46.75 | 2019 | |
| Boston Scientific Corporation | $43.50 | 2025 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $39.00 | 2021-2025 | Simlandi |
| Sobi, INC | $28.41 | 2025 | |
| Mylan Institutional INC. | $25.43 | 2023 | Hulio |
| Tonix Medicines, INC. | $24.74 | 2025 | Tonmya |
| Celltrion USA INC. | $24.50 | 2023 | Yuflyma |
| Pacira Pharmaceuticals Incorporated | $22.21 | 2023 | Iovera, Zilretta |
| Kyowa Kirin, INC. | $21.64 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.94 | 2024 | Crysvita |
| Hikma Pharmaceuticals USA | $20.17 | 2019 | |
| Celgene Corporation | $17.15 | 2019 | |
| Bioventus LLC | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Maestrello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.